Skip to main content

Table 1 Baseline demographic and clinical features of RA patients

From: Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study

Characteristics All patients (n = 56) Non-progressive group (n = 40) Progressive group (n = 16) P*
Demographic     
 Age, yrs, median (IQR) 48 (37 ~ 57) 48 (37 ~ 58) 51 (38 ~ 56) 0.863
 Female, n (%) 43 (77) 33 (83) 10 (63) 0.211
Disease duration, mo, median (IQR) 24 (12 ~ 55) 17 (12 ~ 36) 24 (13 ~ 117) 0.154
 Short duration, n (%) 5 (9) 3 (1) 2 (13) 0.941
 Intermediate duration, n (%) 32 (57) 25 (63) 7 (44) 0.200
 Long duration, n (%) 19 (34) 12 (30) 7 (44) 0.326
Core disease activity indicators     
 ESR (mm/h), median (IQR) 56 (37 ~ 72) 56 (39 ~ 72) 57 (36 ~ 81) 0.856
 CRP (mg/dl), median (IQR) 1.4 (0.7 ~ 3.3) 1.3 (0.6 ~ 3.0) 1.7 (0.9 ~ 5.5) 0.214
 RF (mg/ml), median (IQR) 206 (61 ~ 475) 211 (42 ~ 465) 178 (69 ~ 510) 0.885
 Anti-CCP (U/ml), median (IQR) 132 (32 ~ 300) 78 (26 ~ 300) 178 (53 ~ 425) 0.178
 SDAI, median (IQR) 27.7 (16.0 ~ 39.5) 29.3 (14.2 ~ 42.6) 22.1 (16.3 ~ 36.1) 0.479
 CDAI, median (IQR) 25.0 (14.3 ~ 36.8) 27.0 (13.0 ~ 39.0) 19.0 (15.3 ~ 32.8) 0.345
 DAS28, median (IQR) 5.1 (3.8 ~ 5.9) 5.1 (3.9 ~ 6.1) 4.6 (3.9 ~ 5.7) 0.514
Poor prognosis features     
 Function limitation, n (%) 30 (54) 20 (50) 10 (63) 0.397
 RF positive, n (%) 47 (84) 32 (80) 15 (94) 0.388
 Anti-CCP positive, n (%) 46 (82) 31 (78) 15 (94) 0.295
 Extraarticular disease, n (%) 1 (2)a 0 1 (2) NA
 Bony erosions, n (%) 52 (93) 36 (90) 16 (100) 0.460
 Total Sharp score, median (IQR) 11 (3 ~ 25) 8 (3 ~ 16) 22 (13 ~ 43) 0.003
 Joint narrow score, median (IQR) 6 (1 ~ 13) 3 (1 ~ 8) 11 (6 ~ 25) 0.014
 Erosion score, median (IQR) 5 (2 ~ 13) 4 (1 ~ 7) 13 (8 ~ 20) 0.001
Serum MMP-3 (ng/ml), median (IQR) 175 (57 ~ 365) 123 (45 ~ 276) 316 (195 ~ 563) 0.010
Hepatitis B virus infection, n (%) 5 (9) 2 (5) 3 (19) 0.135
Previous medications     
 DMARDs and corticosteroids naïve, n (%) 26 (46) 21 (53) 5 (31) 0.253
 Corticosteroids, n (%) 17 (30) 11 (28) 6 (38) NA
  Irregular, n (%) 9 (16) 5 (13) 4 (25) NA
  Prednisolone 10 mg/d, n (%) 4 (7) 4 (10) 0 (0) NA
  Prednisolone 5 mg/d, n (%) 4 (7) 2 (5) 2 (13) NA
 Methotrexate, n (%) 21 (38) 12 (30) 9 (56) NA
 Leflunomide, n (%) 10 (18) 7 (18) 3 (19) NA
 Sulfasalazine, n (%) 3 (5) 2 (5) 1 (6) NA
 Hydroxychloroquine, n (%) 7 (13) 3 (8) 4 (25) NA
 Cyclosporin A, n (%) 2 (4) 2 (5) 0 NA
 Infliximab, n (%) 2 (4) 0 2 (12) NA
 YSP, n (%) 2 (4) 2 (5) 0 NA
  1. *Compared between non-progressive group and progressive group by Mann–Whitney rank-sum test
  2. RA rheumatoid arthritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody, DAS28 Disease Activity Score 28-joint assessment, SDAI simplified disease activity index, CDAI clinical disease activity index, YSP recombinant human tumor necrosis factor-α receptorII:IgG Fc fusion protein (Yi SaiPu), IQR interquartile range, NA not applicable
  3. aRA vasculitis